358 related articles for article (PubMed ID: 34609725)
1. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
Neys SFH; Rip J; Hendriks RW; Corneth OBJ
Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
De Bondt M; Renders J; Struyf S; Hellings N
Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
[TBL] [Abstract][Full Text] [Related]
3. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE; Wampole M; Oberoi K
Front Immunol; 2021; 12():662223. PubMed ID: 34803999
[TBL] [Abstract][Full Text] [Related]
4. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
Rip J; Van Der Ploeg EK; Hendriks RW; Corneth OBJ
Crit Rev Immunol; 2018; 38(1):17-62. PubMed ID: 29717662
[TBL] [Abstract][Full Text] [Related]
5. The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C; Xanthopoulos C; Kostareli E
Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
[TBL] [Abstract][Full Text] [Related]
6. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.
Crofford LJ; Nyhoff LE; Sheehan JH; Kendall PL
Expert Rev Clin Immunol; 2016 Jul; 12(7):763-73. PubMed ID: 26864273
[TBL] [Abstract][Full Text] [Related]
7. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
8. Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease.
Rip J; de Bruijn MJW; Appelman MK; Pal Singh S; Hendriks RW; Corneth OBJ
Front Immunol; 2019; 10():95. PubMed ID: 30761150
[TBL] [Abstract][Full Text] [Related]
9. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
10. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
Good L; Benner B; Carson WE
Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
[TBL] [Abstract][Full Text] [Related]
13. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
Das D; Wang J; Hong J
Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Feng Y; Duan W; Cu X; Liang C; Xin M
Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
[TBL] [Abstract][Full Text] [Related]
15. Reduced dosage of Bruton's tyrosine kinase uncouples B cell hyperresponsiveness from autoimmunity in lyn-/- mice.
Whyburn LR; Halcomb KE; Contreras CM; Lowell CA; Witte ON; Satterthwaite AB
J Immunol; 2003 Aug; 171(4):1850-8. PubMed ID: 12902486
[TBL] [Abstract][Full Text] [Related]
16. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
[TBL] [Abstract][Full Text] [Related]
17. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
Lin P; Zhang D; Lin J
Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
[TBL] [Abstract][Full Text] [Related]
19. Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.
Neys SFH; Hendriks RW; Corneth OBJ
Front Cell Dev Biol; 2021; 9():668131. PubMed ID: 34150760
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
